Platelet interaction with a pancreatic ascites tumor

Area of Science:

• Oncology
• Hematology
• Biochemistry

Background:

• The mechanism of hypercoagulability in pancreatic carcinoma remains unclear due to disease progression and tumor inaccessibility.
• A hamster model of pancreatic malignancy was developed to study tumor cell-hemostasis interactions.

Purpose of the Study:

• To investigate in vitro tumor cell-platelet interactions.
• To examine hemostatic changes in hamsters after intravenous tumor cell injection.

Main Methods:

• Freshly isolated pancreatic tumor cells and sonicates were used to induce platelet aggregation in human platelet-rich plasmas (hPRP and cPRP).
• Platelet aggregation, thromboxane formation, and serotonin release were measured.
• Hemostatic parameters (platelet count, antithrombin III, fibrinogen) were assessed in hamsters post-tumor cell infusion.

Main Results:

• Tumor cells induced platelet aggregation, thromboxane formation, and serotonin release, particularly in citrated plasma.
• Platelet aggregation was inhibited by aspirin, apyrase, and PGI2.
• In hamsters, tumor cell infusion led to decreased platelet counts, antithrombin III, and fibrinogen, with observed platelet aggregates and fibrin strands in the lungs.

Conclusions:

• Pancreatic tumor cells directly interact with platelets, leading to aggregation and release of mediators.
• Tumor cell administration causes significant hemostatic disturbances in vivo, contributing to hypercoagulability.